Subscribe
heidi-besen
Heidi Besen / Shutterstock.com
5 June 2020Big PharmaRory O'Neill

Has the public got the taste for free medicine?

The COVID-19 pandemic has seen the fundamental principles of the IP system, normally a touchstone of advanced economies, called into question. Governments and manufacturers alike are under pressure to assure the public that IP will not be a barrier to accessing the tools needed to fight the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York